Want to see TSE:PCLO full AI Analyst Report?
PCLO Stock Chart & Stats
C$0.08
-C$0.01(-13.33%)
At close: 4:00 PM EDT
C$0.08
-C$0.01(-13.33%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume35.78K
Average Volume (3M)0.00
Market Cap
C$13.29M
Enterprise ValueC$26.82
Total Cash (Recent Filing)C$17.52K
Total Debt (Recent Filing)C$19.14M
Price to Earnings (P/E)―
Beta-3.20
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding211,283,630
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Colombian Production FootprintHaving operations centered in Colombia and a stated focus on producing cannabis-derived products for downstream pharmaceutical and regulated markets provides a durable operational base. It supports scale-up of cultivation and extraction capability and positions the company to serve regulated ingredient demand over the medium term.
Improving Gross MarginA positive TTM gross margin (~29%) and material improvement versus 2023 indicate the business is moving toward better unit economics. Sustained gross-margin recovery reduces the break-even revenue threshold and, if maintained, supports a credible path to operating leverage as sales stabilize or grow over the next several quarters.
Growing Asset BaseAn increase in total assets suggests investment in capacity, inventory or facilities that can support future revenue generation. A larger tangible asset base can enable higher production volumes and potential contract supply opportunities in regulated markets if the company converts capacity into consistent sales.
Bears Say
Negative Equity And LeverageNegative equity combined with sizable debt creates persistent solvency and refinancing risk. This structural weakness limits financial flexibility, raises cost of capital, and can restrict the firm's ability to invest or weather shocks absent successful deleveraging or external recapitalization within the medium term.
Ongoing Cash BurnConsistently negative operating and free cash flow (~-$4.6M TTM) shows losses are translating into real cash use. Persistent cash burn reduces runway, forces reliance on external financing, and constrains the company's ability to fund operations or invest in growth without dilutive or costly capital solutions.
Small, Contracting RevenueA very small and sharply contracting revenue base undermines the economics of the business model and makes fixed-cost absorption difficult. With deeply negative operating margins, the company lacks scale, increasing the challenge of reaching sustainable profitability absent material and sustained revenue recovery.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$13.29M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is Aug 14, 2026 which is in 11 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 211,283,630 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―